Letters Incretins and pancreatic cancer

The BMJ and Dispatches gave only one side of the story

BMJ 2013; 347 doi: https://doi.org/10.1136/bmj.f4379 (Published 10 July 2013) Cite this as: BMJ 2013;347:f4379
  1. Richard I G Holt, professor in diabetes and endocrinology1
  1. 1University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK
  1. righ@soton.ac.uk

The BMJ and Channel 4 Dispatches programme “Diet, Drugs and Diabetes” focused on possible dangers of incretin based treatments and alleged that the drug industry is hiding important safety data.1 Although drug safety and transparency are paramount, it is important to remember that no diabetes drug is completely safe. Clinicians and people with diabetes need to make a balanced decision about the risks and benefits of treatment, and this requires …

View Full Text

Log in

Log in through your institution


* For online subscription